TW202227397A - 雙環的-雜環衍生物及相關用途 - Google Patents

雙環的-雜環衍生物及相關用途 Download PDF

Info

Publication number
TW202227397A
TW202227397A TW110132883A TW110132883A TW202227397A TW 202227397 A TW202227397 A TW 202227397A TW 110132883 A TW110132883 A TW 110132883A TW 110132883 A TW110132883 A TW 110132883A TW 202227397 A TW202227397 A TW 202227397A
Authority
TW
Taiwan
Prior art keywords
alkyl
alkenyl
cycloalkyl
alkynyl
aryl
Prior art date
Application number
TW110132883A
Other languages
English (en)
Chinese (zh)
Inventor
布魯斯 樂夫克
卡爾 吉伯森
馬修 史班迪
保羅 哈姆瑞斯
沙拉 柏克奈爾
沃伊切赫 賽沃迪
羅迪克 波特
Original Assignee
英商歐瑞夏治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商歐瑞夏治療公司 filed Critical 英商歐瑞夏治療公司
Publication of TW202227397A publication Critical patent/TW202227397A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW110132883A 2020-09-03 2021-09-03 雙環的-雜環衍生物及相關用途 TW202227397A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063074216P 2020-09-03 2020-09-03
US63/074,216 2020-09-03

Publications (1)

Publication Number Publication Date
TW202227397A true TW202227397A (zh) 2022-07-16

Family

ID=78078375

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110132883A TW202227397A (zh) 2020-09-03 2021-09-03 雙環的-雜環衍生物及相關用途

Country Status (6)

Country Link
US (1) US12503475B2 (OSRAM)
EP (1) EP4208444A1 (OSRAM)
JP (1) JP7840517B2 (OSRAM)
CN (1) CN116583502A (OSRAM)
TW (1) TW202227397A (OSRAM)
WO (1) WO2022051596A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
EP4486445A1 (en) * 2022-03-01 2025-01-08 Centessa Pharmaceuticals (UK) Limited Bicyclic-heterocycle derivatives and related uses
CN115124410B (zh) * 2022-08-13 2024-06-04 上海珂华生物科技有限公司 一种2-氟-4-羟基苯甲醛的制备方法
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
TW202430169A (zh) 2022-12-16 2024-08-01 日商第一三共股份有限公司 2-氮雜雙環[3.1.1]庚烷化合物
WO2024246867A1 (en) 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137359A1 (en) * 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
GB202404750D0 (en) 2024-04-03 2024-05-15 Bial Portela & Ca Sa Orexin receptor agonists
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2025229495A1 (en) * 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20260012686A (ko) * 2024-07-18 2026-01-27 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
ES2703723T3 (es) 2006-12-14 2019-03-12 Exelixis Inc Métodos para usar inhibidores de MEK
WO2008128121A1 (en) 2007-04-12 2008-10-23 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US8030307B2 (en) 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8871794B2 (en) 2008-06-04 2014-10-28 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
LT2513053T (lt) 2009-12-18 2018-01-25 Ogeda Sa Pirolidino karboksirūgščių dariniai kaip su g baltymu sąveikaujančio receptoriaus 43 (gpr43) agonistai, farmacinės kompozicijos ir būdai, skirti naudoti metabolinių susirgimų gydymui
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
US9309236B2 (en) 2011-10-05 2016-04-12 The Board Of Trustees Of The Leland Stanford Junior University PI-kinase inhibitors with broad spectrum anti-infective activity
ITMI20112329A1 (it) 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
CN105916500A (zh) 2013-11-27 2016-08-31 欧洲筛选有限公司 用于治疗炎性疾病的化合物、药物组合物和方法
JP2017523988A (ja) 2014-08-05 2017-08-24 アリオス バイオファーマ インク. パラミクソウイルスを治療するための併用療法
WO2016021629A1 (ja) 2014-08-06 2016-02-11 塩野義製薬株式会社 TrkA阻害活性を有する複素環および炭素環誘導体
EP4438041A3 (en) 2016-02-04 2025-01-01 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
EP3594203B1 (en) 2017-03-08 2021-08-04 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
JP6574918B1 (ja) * 2017-08-03 2019-09-11 武田薬品工業株式会社 複素環化合物およびその用途
WO2019027069A1 (ko) * 2017-08-03 2019-02-07 (주)상아프론테크 연료전지 전해질 강화막 및 이의 제조방법
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US12091410B2 (en) 2018-12-12 2024-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
CN118271298A (zh) * 2019-01-31 2024-07-02 武田药品工业株式会社 杂环化合物及其用途
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
KR20220062361A (ko) 2019-09-13 2022-05-16 다케다 야쿠힌 고교 가부시키가이샤 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도
US20220339143A1 (en) 2019-09-13 2022-10-27 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
JPWO2021065893A1 (OSRAM) 2019-09-30 2021-04-08
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
SI4067344T1 (sl) 2019-11-27 2026-03-31 Sumitomo Pharma Co., Ltd. Cikloalkil-sečninski derivati
US20210200298A1 (en) 2019-12-30 2021-07-01 Advanced Micro Devices, Inc. Long-idle state system and method
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US20230331720A1 (en) 2020-09-03 2023-10-19 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
WO2023017180A1 (en) 2021-08-13 2023-02-16 Orexia Therapeutics Limited Peptide derivatives and related uses as orexin agonists
JP2025507852A (ja) 2022-03-01 2025-03-21 センテッサ ファーマシューティカルズ (ユーケー) リミテッド 中環状または大環状ベンジル置換複素環誘導体および関連の使用
EP4486445A1 (en) 2022-03-01 2025-01-08 Centessa Pharmaceuticals (UK) Limited Bicyclic-heterocycle derivatives and related uses

Also Published As

Publication number Publication date
WO2022051596A1 (en) 2022-03-10
US12503475B2 (en) 2025-12-23
JP2023540344A (ja) 2023-09-22
WO2022051596A8 (en) 2022-04-07
US20230271973A1 (en) 2023-08-31
CN116583502A (zh) 2023-08-11
EP4208444A1 (en) 2023-07-12
JP7840517B2 (ja) 2026-04-06

Similar Documents

Publication Publication Date Title
US12503475B2 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
TW202227433A (zh) 中環或大環之經苄基取代的雜環衍生物及相關用途
CN101687827B (zh) 环状基团取代的氨基二氢噻嗪衍生物
CN105814050B (zh) 用作tnf活性调节剂的吡唑并吡啶衍生物
CN111801318B (zh) 受体抑制剂、包含其的药物组合物及其用途
CN105814053B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN110267962A (zh) Magl抑制剂
TW201734001A (zh) ROR-γ調節劑
WO2018167176A1 (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
TW202317092A (zh) Kif18a之吲哚啉抑制劑
WO2022207935A1 (en) 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
EP4486445A1 (en) Bicyclic-heterocycle derivatives and related uses
TW202134248A (zh) Sstr5拮抗劑
AU2023228830A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
CN111902401B (zh) 受体抑制剂、包含其的药物组合物及其用途
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
CN119403794A (zh) 用于治疗trpm3介导的病症的新型衍生物
WO2021228216A1 (zh) 可用作RORγ调节剂的联芳基类化合物
CN119490501A (zh) 咪唑双环化合物及其制备方法和用途
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用
HK40119559A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物
JP2025537627A (ja) セレン含有複素環式化合物およびその使用
WO2026002203A1 (zh) 组织蛋白酶c抑制剂化合物及其应用